Filippo Gallina
@filippog92
Thoracic Surgeon at IRCCS National Cancer Institute of Rome. Research Fellow at McGill University, Montréal.
“Forse facciamo più schifo che spavento”
💥«Israele è un presidio di legalità», ha detto Matteo Salvini ricevendo il Premio Italia-Israele. È stato assegnato dalle organizzazioni Istituto Milton Friedman, Unione delle Associazioni Italia-Israele, Maccabi World Union, Israel’s Defend & Security Forum (lobby accreditata…
The Israeli Army is now targeting starving children in the head and testicles in Gaza, while terrorising others, together with violent lunatics, in the West Bank. These past 650 days, Israel has written one of the darkest pages of human history. And it is absolutely sickening…
🚨 SHOCKING REPORT: Israeli soldiers in Gaza are reportedly turning the targeting of Palestinian children into a horrifying and systematic “human-hunting game,” according to British surgeon Dr. Nick Maynard. He testified: “These children are being targeted almost as if it’s a…
🚨 New in European Journal of Cancer! TP53 co-mutations in stage I EGFR-mutated LUAD significantly ↑ recurrence risk sciencedirect.com/science/articl… 🎯 Shorter RFS, OS unchanged 💡 Suggests early escalation may be warranted even in resected disease This mutation combo is trouble—TP53…
It seems we are in a bit of a data quagmire. I often get asked how to choose between neoadjuvant versus perioperative immunotherapy and right now there aren’t many great answers, but for what it’s worth, here’s my general perspective… #ASCO25
Spero che la forza morale, la dignità e l’intelligenza etica di questo ragazzino tolgano il sonno a coloro che gli hanno causato o hanno permesso gli si causasse tanto dolore
Il dolore e la rabbia di Ahmad che racconta come vanno le cose nei punti di “aiuto” a Gaza e la verità su tutto: “Mi chiamo Ahmad Mohammad Zaidan. Oggi mia madre è stata uccisa nel centro di distribuzione degli aiuti e prima era stato ucciso mio fratello. L'esercito sionista è
On the subject of identifying patients for novel neoadjuvant trials, I am so very proud of @MeghanDeMeo, PhD student in my lab, for publishing her work examining ddPCR to identify patients with KRAS mutations in early-stage NSCLC. While interesting for stage III, this technology…
Very happy to share this published work done under the supervision of @DoctorJSpicer and in collaboration with @jvburnier and Dr. Pierre-Olivier Fiset! sciencedirect.com/science/articl…
🎙️ Tumore al polmone e immunoterapia Paola Nisticò (IRE) @NisticoLab a @RRCapitale : “Investire in tecnologia e lavorare in équipe è la nostra forza. Così costruiamo una vera medicina di precisione.” 🔬 Scopri lo studio 👉: buff.ly/CliB3p2
Navigational bronchoscopy as the new standard for biopsy of lung nodules? Non-inferiority trial @NEJM compared robotic bronch to transthoracic needle biopsy with similar accuracy (79% vs 74%) but bronch with lower risk of pneumothorax (3.3% vs 28.3%). nejm.org/doi/full/10.10…
Precision medicine for lung cancer 🫁: a new case report from our institute @IREISGufficiale highlights B cells as crucial players in the response to neoadjuvant chemo-immunotherapy therapy. @filippog92 @NiclaPorciello @NisticoPaola
🚨 Just published in @jitcancer: our report on spatial transcriptomics of a resectable NSCLC after neoadjuvant chemo-io. A great multidisciplinary effort by @NisticoLab and @IREISGufficiale! Looking forward to many collaborations in this field. jitc.bmj.com/content/13/5/e…
Thanks @FedericoCappuz1 #LorenzaLandi #TinaCascone for the invitation to speak at #RomeLung25 on early stage oncogene+ NSCLC Priorities : - define optimum TKI duration - ⬇️tox - ⬆️OS Amazing to be in a session with @TonyMok9, @MP_3855 & @marinagarassino…can I retire now? #LCSM
Terrific afternoon sessions at #RomeLung25 - Defining and delivering integrated therapies for stage III requires collaboration across disciplines. - optimal adj duration still unknown @marinagarassino Outstanding programme @FedericoCappuz1 #LorenzaLandi and #TinaCascone
Social ancora disponibile al costo di euro 0
A pleasure to reunite in Bologna with some friends in the thoracic oncology field to discuss the future of resectable lung cancer. Many changes (and challenges) ahead! @Pietrobiella Francesca Ambrosi @filippog92 @dmarinelli93 @AntonioNuccio01 @IASLC
One could easily conceive a trial examining this question with focus on extent of resection, but in my view the path to improved outcomes in this cohort is pre-operative assessment of risk beyond the size criterion with randomization to neoadj therapy vs up front surgery. Will…
Check out our #NCDB analysis of segmentectomy vs lobectomy in cT1cN0M0 #NSCLC +/- path nodal upstaging in #JTCVSOpen @AATSHQ. Limitations in the dataset, but similar outcomes seen in matched cohorts @SamKimMD @AnkitBharatMD @NM_Lung jtcvsopen.org/article/S2666-…
🚨 Just out on @LungCaJournal our considerations on the impressive work done by @MARIANOPROVENCI and the @gecp_org about BRAF mutations and neoadj chemo-IO. @CecereFabiana @FedericoCappuz1 Full text here: sciencedirect.com/science/articl…
Collaboration knows no borders at @IASLC reception #ELCC25 - especially when there's a football table involving Italians and Portuguese s @MarianaBrandao0 @Brunet3Leon @GiuliaLaCavaMD @filippog92